Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

3



Key Takeaways

  • Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).
  • The drug, Dupixent, showed a reduction of at least 30% in the annualized rate of moderate or severe COPD in a pair of Phase 3 studies.
  • The drug was previously approved for the treatment of other conditions, including atopic dermatitis and asthma.

Shares of Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA) .

The drug, Dupixent, is the first biologic medicine approved in the U.S. for the treatment of COPD, a respiratory disease that restricts airflow and damages the lungs. The treatment showed a reduction of at least 30% in the annualized rate of moderate or severe COPD in a pair of Phase 3 studies, the companies reported.

COPD Approval Adds to Drug’s Applications

Dupixent was previously approved for the treatment of other conditions, including atopic dermatitis and asthma.

Shares of Regeneron ticked up 0.2% Friday, while Sanofi shares listed in the U.S. rose 1.1%. The companies’ stocks are up about 19% and 16%, respectively, since the start of the year.